Achievements of the EORTC Soft Tissue and Bone Sarcoma GroupHOHENBERGER, Peter; VAN GLABBEKE, Martine; OUALI, Monia et al.European journal of cancer. Supplement (1990). 2012, Vol 10, Num 1, pp 160-166, issn 1359-6349, 7 p.Article

Progression-free survival rate as primary end point for phase II cancer clinical trials : Application to mesothelioma-the EORTC lung cancer groupFRANCART, Julie; LEGRAND, Catherine; SYLVESTER, Richard et al.Journal of clinical oncology. 2006, Vol 24, Num 19, pp 3007-3012, issn 0732-183X, 6 p.Article

Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocolsDE JONG, Daphne; KOSTER, Ad; HAGENBEEK, Anton et al.Haematologica (Roma). 2009, Vol 94, Num 1, pp 70-77, issn 0390-6078, 8 p.Article

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomasSLEIJFER, Stefan; OUALI, Monia; VAN GLABBEKE, Martine et al.European journal of cancer (1990). 2010, Vol 46, Num 1, pp 72-83, issn 0959-8049, 12 p.Article

Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-hodgkin's lymphomaHAGENBEEK, Anton; EGHBALI, Houchingue; TEODOROVIC, Ivana et al.Journal of clinical oncology. 2006, Vol 24, Num 10, pp 1590-1596, issn 0732-183X, 7 p.Article

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma : A phase II study from the European Organisation for Research and Treatment of cancer soft tissue and bone sarcoma groupLEAHY, Michael; RAY-COQUARD, Isabelle; JUDSON, Ian et al.European journal of cancer (1990). 2007, Vol 43, Num 2, pp 308-315, issn 0959-8049, 8 p.Article

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma GroupJUDSON, Ian; PEIMING MA; VAN OOSTEROM, Allan et al.Cancer chemotherapy and pharmacology. 2005, Vol 55, Num 4, pp 379-386, issn 0344-5704, 8 p.Article

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors : A european organisation for research and treatment of cancer-italian sarcoma group-australasian gastrointestinal trials group studyVAN GLABBEKE, Martine; VERWEIJ, Jaap; HOGENDOORN, Pancras C. W et al.Journal of clinical oncology. 2005, Vol 23, Num 24, pp 5795-5804, issn 0732-183X, 10 p.Article

Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trialsGELDERBLOM, Hans; JINKS, Rachel C; TAMINIAU, Antonie H. M et al.European journal of cancer (1990). 2011, Vol 47, Num 6, pp 895-902, issn 0959-8049, 8 p.Article

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy : A randomized phase III trial of the European osteosarcoma intergroupLEWIS, Ian J; NOOIJ, Marianne A; KIRKPATRICK, Anne et al.Journal of the National Cancer Institute. 2007, Vol 99, Num 2, pp 112-128, issn 0027-8874, 17 p.Article

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursDEBIEC-RYCHTER, Maria; SCIOT, Raf; ZALCBERG, John et al.European journal of cancer (1990). 2006, Vol 42, Num 8, pp 1093-1103, issn 0959-8049, 11 p.Article

Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib : A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)VAN GLABBEKE, Martine; VERWEIJ, Jaap; CASALI, Paolo G et al.European journal of cancer (1990). 2006, Vol 42, Num 14, pp 2277-2285, issn 0959-8049, 9 p.Article

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mgZALCBERG, John R; VERWEIJ, Jaap; CASALI, Paolo G et al.European journal of cancer (1990). 2005, Vol 41, Num 12, pp 1751-1757, issn 0959-8049, 7 p.Article

Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs) : An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylateSCIOT, Raf; DEBIEC-RYCHTER, Maria; DAUGAARD, Soren et al.European journal of cancer (1990). 2008, Vol 44, Num 13, pp 1855-1860, issn 0959-8049, 6 p.Article

Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort studyMOSER, Elizabeth C; NOORDIJK, Evert M; VAN LEEUWEN, Flora E et al.Haematologica (Roma). 2006, Vol 91, Num 11, pp 1481-1488, issn 0390-6078, 8 p.Article

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancerBERNIER, Jacques; DOMENGE, Christian; COGNETTI, Francesco et al.The New England journal of medicine. 2004, Vol 350, Num 19, pp 1945-1952, issn 0028-4793, 8 p.Article

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma GroupVAN OOSTEROM, Allan T; JUDSON, Ian R; VERWEIJ, Jaap et al.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 5, pp S83-S87, issn 1359-6349Conference Paper

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours : a phase I studyVAN OOSTEROM, Allan T; JUDSON, Ian; SILBERMAN, Sandra et al.Lancet (British edition). 2001, Vol 358, Num 9291, pp 1421-1423, issn 0140-6736Article

BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup StudyVAN OERS, Marinus H. J; TÖNNISSEN, Evelyn; HOLTE, Harald et al.Journal of clinical oncology. 2010, Vol 28, Num 13, pp 2246-2252, issn 0732-183X, 7 p.Article

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup StudyVAN OERS, Marinus H. J; VAN GLABBEKE, Martine; HAGENBEEK, Anton et al.Journal of clinical oncology. 2010, Vol 28, Num 17, pp 2853-2858, issn 0732-183X, 6 p.Article

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and LymphomasRAY-COQUARD, Isabelle; CROPET, Claire; GUASTAILA, Jean-Paul et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 13, pp 5383-5391, issn 0008-5472, 9 p.Article

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)SLEIJFER, Stefan; RAY-COQUARD, Isabelle; VAN GLABBEKE, Martine et al.Journal of clinical oncology. 2009, Vol 27, Num 19, pp 3126-3132, issn 0732-183X, 7 p.Article

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-hodgkin lymphoma in patients both with and without rituximab during induction : results of a prospective randomized phase 3 intergroup trial. CommentaryGHIELMINI, Michele; VAN OERS, Marinus H. J; HOLTE, Harald et al.Blood. 2006, Vol 108, Num 10, issn 0006-4971, 3235,3295-3301 [8 p.]Article

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma: Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)FOSSA, Sophie D; MICKISCH, Gerald H. J; DE MULDER, Pieter H. M et al.Cancer. 2004, Vol 101, Num 3, pp 533-540, issn 0008-543X, 8 p.Article

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha―Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor EraCASSIER, Philippe A; FUMAGALLI, Elena; ADENIS, Antoine et al.Clinical cancer research (Print). 2012, Vol 18, Num 16, pp 4458-4464, issn 1078-0432, 7 p.Article